chrisvoncsefalvay/vaers-outcomes huggingface dataset:
the pain from his injection elbow to his shoulder; numbness and tightness that goes from shoulders to chest; numbness and tightness that goes from shoulders to chest; experience arm pain in the injection arm; experience arm pain in the injection arm; This is a spontaneous report from a contactable consumer (patient, self-reported). A 44-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number and expiry date were not reported), via an unspecified route of administration, in Arm, on 20Aug2021 (age at vaccination: 44 years), as a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient reported that on 20Aug2021, at evening, he started to experience arm pain in the injection arm. The following day he stated the arm was still sore and had not stopped hurting since but reports that "some days the pain was not so bad." He described that on an unspecified date the pain from his injection elbow to his shoulder and then numbness and tightness that goes from shoulders to chest. He was calling to report his side effects. Outcome of the events was unknown.  The lot number for BNT162b2 was not provided and will be requested during follow up.
This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant medications were not reported. On 27-OCT-2015, the patient was vaccinated with improperly stored GARDASIL 9 (strength, dose and route of administration were not reported, lot # L007560, expiration date: 15-JUN-2017). No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of the several reports received from the same reporter. Additional information has been requested.
Extreme joint pain in ankles, feet, knees, wrists, and hands.  Could not hold a pencil or walk up stairs.  The symptoms began about 3 weeks post-vaccine.  After several days, they were unbearable and I went to a walk-in clinic.  I was prescribed a 5-day pack of prednisone which alleviate the symptoms.    The week of July 26th, the symptoms returned but were more focused on my hands, wrists, and fingers.  Ankles & feet were also sore but I could, again, not hold anything in my hands, or bend my fingers.  Extreme fatigue accompanied this flare. Provider prescribed another course of prednisone and maloxican.
THE INJECTION WAS INTO MY LEFT UPPER ARM. WITHIN A FEW HOURS, I FELT PAIN WHCH GRADUALLY BECAME EXTREMELY INTENSE.   MY LEFT UPPER ARM WAS TOTALLY RIGID & NON-FUNCTIONAL.  A VIST TO THE DOCTOR AFTER 10 DAYS, REVEALED A SEVERELY INFLAMED DELTOID MUSCLE.  IT STILL HAS NOT ABATED TOTALLY.  IT GOES INTO SPASM IF I TRY TO MOVE IT AND  IT HAS SPREAD TO MY SHOULDER. DR. PRESCRIBED AN ANTI-INFLAMMATORY CREAM, VOLTARIN.
On 8/22/2021 at 3:05pm I received my 3rd dose of Pfizer Covid vaccine.  At 1:15am on 8/23/2021 I had a wave of nausea followed by horrible pain in my chest.  It felt like someone wrapped my chest tightly and laid a ton of bricks on top of my chest. Around 2:15am I was transported to Medical Center where I was monitored. Tests were run that were negative.  I was released at 6am promising the ER doctor that I would contact my Cardiologist that morning. My cardiologist ran a bunch of tests  on 8/24/2021 and diagnosed me with Covid related Myocarditis.
Red area around injection site,  6 x 5cm,  hard, hot, dark red.  Hematoma 4x4 cm above the site.  No fever, no pain to the extent I needed pain killer. Uncomfortable and pulsating and itchy. Today, day 15 after vaccination:  Induration 70% resolved, size increased since day 12 by 0.5 to 1.0 cm, colour has changed on the edges to dark pink except in the center. Lymphnodes right axilla swollen tender to touch
Patient has shingles . Date of vaccine was 2/3/21 Onset of shingles rash was 2/24/21 Upper back/flank rash  Confirmed by medical provider on 3/1/21
Temperature of 100.2 with chills; nausea; tiredness; general malaise; temperature of 100.2; This is a spontaneous report from a contactable Nurse (patient). A 73-year-old non-pregnant female patient received first dose of bnt162b2 (Pfizer covid-19 vaccine, Solution for injection, Lot number: EL3302), via an intramuscular route in the left arm on 11Feb2021 at 15:15 (age at vaccination: 73-year-old), as a single dose for covid-19 immunization. Medical history included covid. Concomitant medication included raloxifene hydrochloride (EVISTA) 60 md qd. No known allergies were reported. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Since the vaccination, patient has not been tested for COVID-19. On 12Feb2021 at 08:00, patient experienced temperature of 100.2 with chills, nausea, tiredness and general malaise. Patient did not receive any treatment for the events. The patient underwent lab test and procedure which included temperature of 100.2 with chills on 12Feb2021. The clinical outcome of the events was recovered.  Follow-up attempts completed. No further information expected.
Initial exam was significant for normal vital signs, urticaria to back, neck and left forearm. Mild tenderness to palpation to LLQ. No oral edema was appreciable, pulmonary exam without wheezing, cardiac exam with RRR. Initial epi pen was administered. Patient continued to endorse worsening urticaria and itch as well as chest tightness and second dose of epinephrine was administered approximately 8 minutes later. His oxygen levels dropped to the 92-94% so supplemental O2 was initiated via a non rebreather. On transfer to EMS team, patient was in stable condition.
Encephalitis picture with initial seizure, followed by basal ganglia signs, (L) hemiparesis. CNS abnormalities persist. Will need long-term rehab.
myocarditis; This is a spontaneous report received from a non-contactable reporter (Consumer or other non HCP) from medical information team for a Pfizer sponsored program.  A 24 year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection) (Batch/Lot number: unknown) as dose 1, single and (Batch/Lot number: unknown) as dose 2, single for COVID-19 immunization. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MYOCARDITIS (medically significant), outcome "unknown," described as "myocarditis." The reporting family member wanted to know if the patient could proceed with the booster dose.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
COVID arm. Slight itchiness, tender and warm to touch. Hard as a ball. Red like a rash, slowly getting bigger.
This spontaneous report was received from the registered medical officer manager referring to an unknown number of patients of unknown age and gender. The patients medical histories and concurrent conditions were not reported. On unspecified dates in 2015, reported "since 24-JUN-2015", the patients were vaccinated with improperly stored doses of (Oka/Merck) VARIVAX (lot # K002928, expiration date: 26-FEB-2016; lot # J012210, expiration date 28-SEP-2015) (dose and route of administration were not reported). Concomitant medications were not reported. No adverse effects reported. There was no product quality involved. This is one of the several reports from the same source. Additional information has been requested.
Hard raised red bump at injection site.  About 2x1 inches. Painful to the touch and a bit warm
On Monday, 8/30 after overcoming lethargy from the vaccine I developed numbness and tingling in both hands and forearms, this spread to lips, tongue and mouth by end of day Monday.   By Thursday, 9/2 even this became so intense that I visited the ER, and there they hypothesized it was potentially from the vaccine and to ride it out.  By Friday, 9/3 midday the numbness started in my left big toe.  This quickly moved to both big toes.  Each day since the paresthesia has spread further in both feet.  Today 9/9 it consumes all toes and the balls of both feet.  On 9/6 I went to the ER.  There they diagnosed that I was hyperventilating causing the the paresthesia to spread.
SHORTNESS OF BREATH; HEADACHE; MUSCLE ACHES; FATIGUE; SINUS (CONGESTION/RUNNY NOSE); LITTLE COUGH; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, and batch number: UNKNOWN expiry: UNKNOWN) .5 ml, administered on 04-MAR-2021 for prophylactic vaccination. Batch numbers have been requested. No concomitant medications were reported. On 04-MAR-2021, the patient experienced shortness of breath. On 04-MAR-2021, the patient experienced headache. On 04-MAR-2021, the patient experienced muscle aches. On 04-MAR-2021, the patient experienced fatigue. On 04-MAR-2021, the patient experienced sinus (congestion/runny nose). On 04-MAR-2021, the patient experienced little cough. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from shortness of breath, muscle aches, fatigue, sinus (congestion/runny nose), and little cough, and the outcome of headache was not reported. This report was non-serious.
19 YO male received the first dose of the Engerix-B adult vaccine inadvertently; 19 YO male received the first dose of the Engerix-B adult; This case was reported by a pharmacist via call center representative and described the occurrence of accidental overdose in a 19-year-old male patient who received HBV (Engerix B adult) for prophylaxis.   In September 2021, the patient received the 1st dose of Engerix B adult. In September 2021, unknown after receiving Engerix B adult, the patient experienced accidental overdose and adult product administered to child. On an unknown date, the outcome of the accidental overdose and adult product administered to child were unknown.  Additional details were provided as follows: The 19 years old patient received dose of Engerix-B adult inadvertently about two and a half (2.5) weeks ago of the date of reporting, which led to accidental overdose and adult product administered to child. The reporter consented to follow up
Information has been received from a medical assistant concerning multiple unknown patients of unknown age and gender. The patients' concurrent conditions, medical histories and concomitant therapies were not provided. On unknown dates, the patients were vaccinated with doses of improperly stored RECOMBIVAX HB 5 mcg/0.5 ml intramuscular injection (lot # L045117 with expiration date 06-OCT-2018, lot # M001578 with expiration date 02-NOV-2018; dose and route were unknown). The vaccines were exposed to temperature excursion of 47.8 degrees Fahrenheit for 67 hours. There were no previous temperature excursions. No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Within 5 minutes i was dizzy, lost vision, could hold items, and vomiting. After vomiting i felt a little netyer and got vision back, but still very shaky dizzy and out of it.
Shingles; Information was received from a lawyer regarding a case in litigation and refers to a male patient of unknown age. The patient's medical history and concomitant therapy were nor reported. In or around 01-AUG-2017, the patient was vaccinated with a dose of zoster vaccine live (ZOSTAVAX) (dose, route of administration, lot # and expiration date were not reported) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after receiving zoster vaccine live (ZOSTAVAX), patient suffered a rash in left arm, fingers, shoulder blades, under the rib cage of right arm and right leg and pain within arms and legs and was diagnosed with shingles. As a direct and proximate result of defective zoster vaccine live (ZOSTAVAX) vaccine, patient's symptoms have resulted in physical limitations not present prior to using zoster vaccine live (ZOSTAVAX). Patient also experiences mental and emotional distress due to resulting physical limitations and seriousness of his condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), patient sustained severe and permanent personal injuries. Further, as a permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of company's conduct, patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. Outcome of the shingles was not reported. The event of shingles was considered to be related to zoster vaccine live (ZOSTAVAX).
hives rash; seen by MD dx extensive urticarial reaction; given DPh;
Started with headache early in the morning (~8AM), progressed to intense headache by noon. Nausea. Some chills. All symptoms gone by next morning, 7AM. Mild nausea persisted until mid morning. No treatment, just rest.
Developed illness; Tested positive for COVID19 Virus; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Developed illness) and COVID-19 (Tested positive for COVID19 Virus) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L21A) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes and Hypertension.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jan-2021, the patient experienced ILLNESS (Developed illness) and COVID-19 (Tested positive for COVID19 Virus). On 30-Jan-2021, COVID-19 (Tested positive for COVID19 Virus) had resolved. At the time of the report, ILLNESS (Developed illness) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 09-Jan-2021, SARS-CoV-2 test: positive (Positive) Tested positive for COVID-19 and recovered on 30 JAN 2021.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication included Diabetic medications and High Blood Pressure medication.  No treatment information was provided.
The day after the vaccine my ears all of a sudden felt congested the I heard high pitched ringing sound in both ears. This continued intermittently. I reported to  VAERS in texts that I received inquiring about vaccine side effects. I also reported this to my physician. My physician thought it was related to vaccine and would go away. It did not. The ringing is not as loud now but is constant. I saw my physician today about this problem. She examined me and requested I report it to you on your website. I have a Eustachian tube dysfunction due to inflammation following the COVID vaccine. I have never had a problem with my Eustachian Tubes prior to this. You may contact her with questions.
Pt stated she developed rash and itching two days after vaccination and forgot to mention to the nurse she had "tetanus shot" previously after delivery on 7/13/12 and developed rash and itching few days afterwards.
Large local reaction of erythema, induration, and tenderness at varicella site (8 X 11 cm) and at Tdap site (5 X 3 cm).
Body aches, low-grade fever, arm pain, Body Chills, Headache, dizziness. Started at 8:00pm on 1/5/21 and lasted until 12:00pm on 1/6/21.
The morning after the vaccine was given (2/2/2021) had body aches, headache, felt cold and felt like had the flu.  On 2/4/2021 she felt much better but still had a headache.
vaccinated with both of the vaccines/ shingles/ suspected vaccination failure; shingles; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis and COVID-19 VACCINE for prophylaxis.   The patient's past medical history included shingles (had shingles several times).   On an unknown date, the patient received the 1st dose of Shingles vaccine, the 2nd dose of Shingles vaccine and COVID-19 VACCINE. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. The patient was treated with valaciclovir hydrochloride (Valtrex). On an unknown date, the outcome of the vaccination failure was unknown and the outcome of the shingles was recovered/resolved.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.  Additional details were provided as follows: The case was self-reported by the patient. The age at vaccination was not reported. The reporter was vaccinated with both of the vaccines and stated that, his/her shingles were not very painful and went away a few days after taking Valtrex. The patient stated that, he/she kept a prescription of Valtrex with him/her everywhere to start it immediately.  The patient had his/her latest episode a few hours after the Covid vaccination. It was unknown if the reporter considered the shingles to be related to Covid-19 vaccine. The follow-up would not possible as no contact details were available. This case was considered as suspected vaccination failure as details regarding the laboratory test confirming shingles and time to onset for shingles were unknown at the time of reporting.
CHILLS; INFLAMED LEFT ARM FROM SITE OF  INJECTION; NAUSEA; HEADACHE; PAIN RADIATING FROM PREVIOUS COLLAR BONE INJURY; MIGRAINE; LEFT-SIDE OF BODY ACHING; COULDN'T SLEEP; This spontaneous report received from a patient concerned a 32 year old female. The patient's height, and weight were not reported. The patient's past medical history included exposure to covid-19, and collar bone injury, and concurrent conditions included diabetic, and other pre-existing medical conditions included patient had no known drug allergies .she was taking pain medication for back and fee (using for 13 years).The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown) .5 ml, administered on 08-MAR-2021 14:00 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 09-MAR-2021, the subject experienced pain radiating from previous collar bone injury. On 09-MAR-2021, the subject experienced migraine. On 09-MAR-2021, the subject experienced left-side of body aching. On 09-MAR-2021, the subject experienced couldn't sleep. On 09-MAR-2021, the subject experienced inflamed left arm from site of injection. On 09-MAR-2021, the subject experienced nausea. On 09-MAR-2021, the subject experienced headache. On 09-MAR-2021 02:00, the subject experienced chills. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from left-side of body aching, couldn't sleep, chills, inflamed left arm from site of injection, and nausea on 09-MAR-2021, and had not recovered from headache, pain radiating from previous collar bone injury, and migraine. This report was non-serious.
Fever, muscle aches, tingling in hands and feet, chest tightness, chest heaviness, dyspnea, calf pain and redness, calf bruising, difficulty catching breath
she lost her taste and smell; she lost her taste and smell; tired; This is a spontaneous report received from contactable consumer (patient) via a Pfizer sponsored program.  A female patient of unspecified age received the first dose of bnt162b2 (COMIRNATY, solution for injection, Batch/Lot Number: Unknown), via an unspecified route of administration on 30Jan2021 at a single dose for covid-19 immunization. The patient medical history and concomitant medications were not reported. On an unspecified date in 2021 (reported as Saturday), the patient felt tired and on 01Feb2021 yesterday (as per report) she lost her taste and smell and asked if that is normal. The outcome of the events was unknown.  This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected.
This spontaneous report as received from a Nurse refers to a 16 year old female patient. The patient pertinent medical history included preemie and chronic rhinitis. On 02-APR-2014, the patient was vaccinated with first dose of GARDASIL lot # J011960 (one vial) intramuscular. Concomitant medication included NEXIUM. On 02-APR-2014, in the evening, the patient experienced a diffuse rash that began her arms which gradually spread to her whole body. It was reported that the rash was treated with BENADRYL and other unspecified histamine products on unspecified dates. On an unknown date in April 2014, the patient underwent laboratory studies was 62 absolute reactive lymphocytes. On an unknown date in April 2014 (also reported as 15 days or 2 weeks ago) the patient experienced general malaise. The outcome of the event was reported as not recovered. The reporter did not provide the causality between the event and the suspect drug. Additional information has been requested.
Rash on arm below injection site (both times) Chills, headache, muscle pain, nausea (second shot)
Developed tenderness and sensitivity under left arm on rib cage / upper torso area approximately 2 weeks after 2nd dose. It was initially suspected to be a rash or allergic reaction, however there was no redness or visible signs of a rash in the area. Approximately 20 days after 2nd vaccine dose, severe migraine headache occurred which lasted for approximately 6 days. After about 3 days of headaches, COVID-19 test was taken and confirmed negative. This was followed by a visit to urgent care facility. Shot of Toradol was given for the headaches and an anti-inflammatory  prescription was provided. Also mentioned to the nurse practitioner the sensitivity at left rib cage / upper torso area. It was confirmed by a nurse practitioner to be early signs of shingles. Prednisone and anti-viral were prescribed for the shingles outbreak. Thankfully the shingles were caught early enough to be treated immediately and I only missed 5 days of work (Mar 24- Mar 30) and the shingles did not develop into large blisters or boils.
Moderna COVID-19 Vaccine EUA   -- left arm very painful with fingers tingling similar to when your hand falls asleep.  No swelling or redness at injection site; fingers not swollen and no loss of color.
I started feeling fatigued/but I thought the same when you got yours; slightly achey/but I thought the same when you got yours.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (dose 1), for COVID-19 immunisation. The following information was reported: FATIGUE (non-serious), outcome "unknown", described as "I started feeling fatigued/but I thought the same when you got yours"; PAIN (non-serious), outcome "unknown", described as "slightly achey/but I thought the same when you got yours.". Additional information: My husband got the his #2 vaccine and I started feeling fatigued and slightly achey two days later. When I mentioned it he said, funny but I thought the same when you got yours. Seemed to be more than coincidence or sympathetic reaction.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.